Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.42 |
| ▸ | PREP | P48147 | 2/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31540 | 1.00 | HPGD (0.48) | HPGDMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL23779404 | 0.95 | HPGD (0.50) | HPGDMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL23779406 | 0.95 | HPGD (0.50) | HPGDMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL28002373 | 0.90 | HPGD (0.48) | HPGDMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL16018 | 0.90 | NR1H2 (0.47) | HPGDMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL16843 | 0.90 | NR1H2 (0.47) | HPGDMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL105348 | 0.90 | NR1H2 (0.47) | HPGDMEN1KMT2AMAPTALDH1A1 | |
| Hydrochloric Acid SCHEMBL25337897 | 0.89 | NR1H2 (0.46) | HPGDMEN1KMT2AMAPTALDH1A1 | |
| Piperazine SCHEMBL28853588 | 0.87 | NR1H2 (0.45) | HPGDMEN1KMT2AMAPTALDH1A1 | |
| Urea SCHEMBL4467391 | 0.86 | NR1H2 (0.44) | HPGDMEN1KMT2AMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118580192-B | Preparation method of chiral intermediate of drug for treating ocular hypertension | 安徽峆一药业股份有限公司 | 2025-09-19 | — | — | CN | disclosed |
| US-20250129095-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INTL GMBH CORP (DE) | 2025-04-24 | — | — | US | disclosed |
| US-20250002504-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM RCV GMBH & CO. KG (AT) | 2025-01-02 | — | — | US | disclosed |
| CN-119013272-A | Cyclic 2-amino-3-cyanothiophenes and derivatives thereof for the treatment of cancer | 勃林格殷格翰国际有限公司 | 2024-11-22 | — | — | CN | disclosed |
| EP-4441055-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | Boehringer Ingelheim International GmbH (DE) | 2024-10-09 | — | — | EP | disclosed |
| CN-118580192-A | Preparation method of chiral intermediate of drug for treating ocular hypertension | 安徽峆一药业股份有限公司 | 2024-09-03 | — | — | CN | disclosed |
| CN-118580192-A | Preparation method of chiral intermediate of drug for treating ocular hypertension | 安徽峆一药业股份有限公司 | 2024-09-03 | — | — | CN | disclosed |
| US-12060367-B2 | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-08-13 | — | — | US | disclosed |
| US-20240174690-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | VANDERBILT UNIVERSITY | 2024-05-30 | — | — | US | disclosed |
| EP-4306520-A1 | THIOPHENE COMPOUND AND APPLICATION THEREOF | Medshine Discovery Inc. (CN) | 2024-01-17 | — | — | EP | disclosed |
| US-20130144054-A1 | NOVEL PRODUCTION METHOD FOR ISOQUINOLINE DERIVATIVES AND SALTS THEREOF | KOWA CO., LTD. (JP) | 2013-06-06 | — | — | US | disclosed |
| EP-2049529-B1 | SUBSTITUTED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2010-08-11 | — | — | EP | disclosed |
| US-20090192143-A1 | Substituted diazepan orexin receptor antagonists | MERCK SHARP & DOHME CORP. | 2009-07-30 | — | — | US | disclosed |
| US-20090192143-A1 | Substituted diazepan orexin receptor antagonists | MERCK SHARP & DOHME CORP. | 2009-07-30 | — | — | US | disclosed |
| US-20090192143-A1 | Substituted diazepan orexin receptor antagonists | MERCK SHARP & DOHME CORP. | 2009-07-30 | — | — | US | disclosed |
| WO-2008008518-A1 | SUBSTITUTED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| EP-0885888-B1 | ISOQUINOLINE DERIVATIVES AND DRUGS | HIDAKA HIROYOSHI DR (JP) | 2003-08-13 | — | — | EP | disclosed |
| EP-1074545-A1 | ISOQUINOLINESULFONAMIDE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | Hidaka, Hiroyoshi (JP) | 2001-02-07 | — | — | EP | disclosed |
| US-6153608-A | Isoquinoline derivatives and drugs | NIPPON SHINYAKU CO., LTD. (JP) | 2000-11-28 | — | — | US | disclosed |
| EP-0885888-A1 | ISOQUINOLINE DERIVATIVES AND DRUGS | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1998-12-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130144054-A1 | NOVEL PRODUCTION METHOD FOR ISOQUINOLINE DERIVATIVES AND SALTS THEREOF | NOS2, NOS3, NOS1 | HPGD 135/4885MEN1 2569/4885KMT2A 4399/4885 |
| US-20250002504-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | KRAS, NRAS, TP53 | HPGD 3215/4885MEN1 559/4885KMT2A 832/4885 |
| US-20090192143-A1 | Substituted diazepan orexin receptor antagonists | HCRTR2, HCRTR1, CRHR1 | HPGD 945/4885MEN1 1250/4885KMT2A 790/4885 |
| US-20250129095-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | RSU1, KRAS, NRAS | HPGD 4499/4885MEN1 1212/4885KMT2A 790/4885 |
| US-20240174690-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | KRAS, NRAS, TP53 | HPGD 3215/4885MEN1 559/4885KMT2A 832/4885 |
| US-12060367-B2 | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer | KRAS, NRAS, TP53 | HPGD 3215/4885MEN1 559/4885KMT2A 832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.